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Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests
for Giant Cell Arteritis
A Systematic Review andMeta-analysis
Kornelis S. M. van der Geest, MD, PhD; Maria Sandovici, MD, PhD; Elisabeth Brouwer, MD, PhD; Sarah L. Mackie, MD, PhD
IMPORTANCE Current clinical guidelines recommend selecting diagnostic tests for giant cell
arteritis (GCA) based on pretest probability that the disease is present, but how pretest
probability should be estimated remains unclear.
OBJECTIVE To evaluate the diagnostic accuracy of symptoms, physical signs, and laboratory
tests for suspected GCA.
DATA SOURCES PubMed, EMBASE, and the Cochrane Database of Systematic Reviews were
searched fromNovember 1940 through April 5, 2020.
STUDY SELECTION Trials and observational studies describing patients with suspected GCA,
using an appropriate reference standard for GCA (temporal artery biopsy, imaging test, or
clinical diagnosis), and with available data for at least 1 symptom, physical sign, or laboratory
test.
DATA EXTRACTION AND SYNTHESIS Screening, full text review, quality assessment, and data
extraction by 2 investigators. Diagnostic test meta-analysis used a bivariate model.
MAIN OUTCOME(S) ANDMEASURES Diagnostic accuracy parameters, including positive and
negative likelihood ratios (LRs).
RESULTS In 68 unique studies (14 037 unique patients with suspected GCA; of 7798 patients
with sex reported, 5193 were women [66.6%]), findings associated with a diagnosis of GCA
included limb claudication (positive LR, 6.01; 95% CI, 1.38-26.16), jaw claudication (positive
LR, 4.90; 95% CI, 3.74-6.41), temporal artery thickening (positive LR, 4.70; 95% CI,
2.65-8.33), temporal artery loss of pulse (positive LR, 3.25; 95% CI, 2.49-4.23), platelet count
of greater than 400 × 103/μL (positive LR, 3.75; 95% CI, 2.12-6.64), temporal tenderness
(positive LR, 3.14; 95% CI, 1.14-8.65), and erythrocyte sedimentation rate greater than 100
mm/h (positive LR, 3.11; 95% CI, 1.43-6.78). Findings that were associated with absence of
GCA included the absence of erythrocyte sedimentation rate of greater than 40mm/h
(negative LR, 0.18; 95% CI, 0.08-0.44), absence of C-reactive protein level of 2.5 mg/dL or
more (negative LR, 0.38; 95% CI, 0.25-0.59), and absence of age over 70 years (negative LR,
0.48; 95% CI, 0.27-0.86).
CONCLUSIONS AND RELEVANCE This study identifies the clinical and laboratory features that
are most informative for a diagnosis of GCA, although no single feature was strong enough to
confirm or refute the diagnosis if taken alone. Combinations of these symptomsmight help
direct further investigation, such as vascular imaging, temporal artery biopsy, or seeking
evaluation for alternative diagnoses.
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G iant cell arteritis (GCA) is a “do-not-miss” diagnosis.Promptdiagnosis can avert visual loss.1 Diagnosis canbe delayed in those without the classic cranial fea-
tures, such as headache.2 Treatment forGCAconsists of high-
dose glucocorticoids tapered during the course of 1 year or
more, but this treatment may cause substantial toxic effects,
so diagnostic uncertainty must be minimized.3
Making adiagnosis ofGCAcanbe challenging. TheAmeri-
can College of Rheumatology 1990 criteria for the classifica-
tion of GCA in research studies should not be used for clinical
diagnosis.4,5 Instead, temporal arterybiopsy (TAB;highly spe-
cific butwith imperfect sensitivity),6 vascular imaging (ultra-
sonography, computed tomography, magnetic resonance
imaging, or positron emission tomography),7 or a combina-
tion of these tests are recommended.3,7 These further inves-
tigationsshouldbeselectedbasedonpretestprobability.3,7The
difficulty inpractice ishowtoquantifypretestprobabilitygiven
only symptoms, signs, and, if available, laboratory features.
Regression, machine learningmodels, or clinical scoring sys-
tems have been suggested, but these rely on complete infor-
mationand still require further validation.8,9 Pretest probabil-
itymight additionally be estimated by using likelihood ratios
(LRs) of clinical features to allow sequential bayesian prob-
ability revision.10 Apreviousmeta-analysis11 reportedpooled
estimates of the LRs of clinical and laboratory features for a
positiveTAB finding.However, thispreviousmeta-analysis in-
cluded studies comparingTAB-positive vsTAB-negativeGCA,
which is not appropriate for estimating diagnostic accuracy.
The previous meta-analysis also included diagnostic case-
control studies, which often overestimate diagnostic
accuracy.12,13 Since the earliermeta-analysis,11manymore rel-
evant studies have been published.14-17
We conducted a systematic review and meta-analysis of
thediagnostic accuracyof symptoms,physical signs, and labo-
ratory tests forGCA.Weprovidesummaryestimatesof thesen-
sitivity, specificity, andLRsof these features.We includedstud-
ies using appropriate reference standards for GCA, including
TAB and clinical diagnosis.We excluded case-control studies
andstudies inwhichall patientswereclassifiedashavingGCA.
Methods
This study is reported in accordancewith the 2009 Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) reporting guideline.18 A predefined study protocol
was established but not registered. No ethical approval or
informed consent was required for the current systematic
review andmeta-analysis.
Data Sources and Search Strategy
We searched PubMed, EMBASE, and the Cochrane Database
of Systematic Reviews fromDecember 1940 to April 5, 2020.
The search strategy included terms such as giant cell arteritis,
temporal arteritis, medical history taking, physical examina-
tion,diagnostic imaging, andarterybiopsy. The full searchstrat-
egy was developed together with an experienced medical
science librarian (eTable 1 in the Supplement). We included
English language records. Case reports and conference ab-
stracts were excluded. The reference lists of included studies
were screened for additional records.
Study Selection and Eligibility Criteria
Weincludedclinical trials andprospectiveor retrospectiveob-
servational studies thatmet the following criteria: (1) partici-
pants were consecutive patients suspected of having GCA;
(2) a TAB, imaging test, or clinical diagnosis was used as the
reference standard for GCA; (3) a table of the true-positive,
false-positive, true-negative, and false-negative counts was
either directly available or could be calculated for at least 1 in-
dex test (symptom, physical sign, or laboratory test); and
(4) at least 5 patients hadGCAand at least 5 did not haveGCA.
The reference standard clinical diagnosis couldbebasedonde-
fined criteria or judgment of 1 ormore physicians.We consid-
ered healed temporal arteritis (ie, intimal hyperplasia and/or
internal elastic lamina disruption in the absence of an arterial
inflammatory infiltrate) as a negative TAB result, because it
might indicate atherosclerosis rather than GCA.6 We ex-
cluded studies inwhich all patientswere diagnosedwithGCA
and/or the closely related disease polymyalgia rheumatica.19
We excluded case-control studies. Titles and abstracts were
screened by 2 independent reviewers (K.S.M.vdG. and M.S.).
Full texts were independently assessed in Covidence by 2 re-
viewers (K.S.M.vdG. and M.S. or S.L.M.). Disagreement be-
tween reviewers was resolved by consensus or, if consensus
couldnotbeobtained,byconsultinga third reviewer (E.B.)who
made the final decision.
Data Collection
Study characteristics and data from 2 × 2 tables were ex-
tractedby 1 reviewer (K.S.M.vdG.) andcheckedbya second re-
viewer (E.B. or S.L.M.). A standardizeddata sheetwasused to
collect informationon study characteristics (eAppendix in the
Supplement). We extracted any clinical or laboratory finding
reported, as well as data on age and sex. Composite findings
(eg, symptomAplus symptomB)were not recorded. Authors
of studies were not contacted. If potential data overlap ex-
isted among studies from the same hospital, data were ob-
tained from the largest study. Whenmultiple reference stan-
dardswere available in 1 study, the clinical diagnosiswasused
Key Points
Question In patients with suspected giant cell arteritis, which
clinical and laboratory findings can help to identify the disease?
Findings This systematic review andmeta-analysis of 68 unique
diagnostic cohort studies (14 037 unique patients) identified
combinations of symptoms, physical signs, and laboratory tests
that were informative with regard to the presence or absence of
giant cell arteritis, but no single feature taken alone. Headache and
scalp tenderness were poorly informative in this population.
Meaning These findings suggest that in patients with suspected
giant cell arteritis, no single clinical or laboratory feature is
sufficient to rule in or rule out the disease; therefore, additional
investigations (vascular imaging and/or temporal artery biopsy)
are required.
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as the reference standard for the main study analysis. A
C-reactive protein (CRP) level of less than 0.5 mg/dL (to con-
vert to mg/L, multiply by 10) was considered the reference
value unless other laboratory-specific reference values were
reported. Disagreement between reviewers was either re-
solved by consensus or, if consensus could not be obtained,
by consulting a third reviewer (E.B. or S.L.M.), whomade the
final decision.
Quality Assessment
The risk of biaswas evaluated by 2 reviewers (K.S.M.vdG. and
E.B.)with thequality assessment of diagnostic accuracy stud-
ies (QUADAS-2) tool (eAppendix in the Supplement). The
QUADAS-2 tool focuses on the bias and applicability of study
results regarding patient selection, the index test, the refer-
ence standard, and study flow and timing.20
Synthesis of Results
Study heterogeneity was evaluated by plotting the estimates
of sensitivity and specificity in forest plots and receiver oper-
ating characteristics (ROC) space. We used hierarchical logis-
tic regression modeling to determine summary estimates of
the sensitivity, specificity, diagnostic odds ratio, and LRs by
the bivariate model approach, as well as hierarchical sum-
mary ROC (HSROC) plots.21 Likelihood ratios of greater than
2.00 or less than 0.50 with 95% CIs not including 1.00 were
considered statistically significant.10,22Weperformed the fol-
lowing sensitivity analyses: (1) apredefinedcomparisonofLRs
in studiesusingdistinct reference standards forGCA; (2) anon-
predefined comparison of LRs in prospective and retrospec-
tive studies; and (3) a predefined analysis restricted to pre-
treatment laboratory tests.Ourprimaryanalysisandsensitivity
analyses included any index test reported by 4 or more stud-
ies. Hierarchical logistic regression modeling analysis and
evaluationof funnelplotasymmetrywereperformedinSTATA,
version 15.1 (StataCorp LLC) with the metandi, metandiplot,
andmidas commands.23 Forest plots were created in Review
Manager,version5.3 (Cochrane)andStatsDirect, version3.2.10
(StatsDirect Ltd).
Results
Study Characteristics
Of the 1436 reports screened, 68 studies14-17,24-87 fulfilled the
selection criteria and were used for the systematic review
and meta-analysis (eFigure 1 in the Supplement). These
studies included 14 037 patients, of whom 4277 (30.5%)
were classified as having GCA (Table 1 and eTable 2 in the
Supplement). Most reports were retrospective cohort studies
(48 [70.6%])14,15,27,29,31,32,34-41,43-46,48-51,53,54,58,59,62,64-68,70-75,
7 7 -8 1 ,83 -87 and performed at academic centers (56
[82.4%]).16,17,24-35,37,38,40-57,59-62,66-69,72,73,75-84,86,87 TAB was
the reference standard in 38 studies (55.9%).14-16,26,30,32,37-45,
48,49,52,56,58-60,62,64,65,67,70,72,73,78-81,83-87 The mean or the
median length of the TAB specimen was generally greater
than 1 cm. A variable proportion of patients underwent
bilateral TAB (eTable 3 in the Supplement). In 30 studies
(44.1%),17,24,25,27-29,31,33-36,46,47,50,51,53-55,57,61,63,66,68,69,71,74-77,82 clinical
diagnosis was the reference standard for GCA; in 8 of these
studies,31,46,53,71,75-77,82 all patients underwent TAB, and in 9
studies,17,33,47,51,61,63,68,69,74 patients had a combination of
TAB and imaging (eTable 4 in the Supplement). The clinical
Table 1. Characteristics of the 68 Included Studies
Characteristic
No. (%)a
Studies
(n = 68)
Patients
(n = 14 037)b
Year of publication
Before 1990 9 (13.2) 797 (5.7)
1990-1999 6 (8.8) 1235 (8.8)
2000-2009 13 (19.1) 2119 (15.1)
2010-2019 40 (58.8) 9886 (70.4)
Study design
Prospective cohort 20 (29.4) 2104 (15.0)
Retrospective cohort 48 (70.6) 11 933 (85.0)
Setting of care
Nonacademic center 7 (10.3) 664 (4.7)
Academic center 56 (82.4) 7777 (55.4)
Nonacademic/academic center 4 (5.9) 3155 (22.5)
Unclear 1 (1.5) 2441 (17.4)
Identification of patients
Central pathology/surgery registry 28 (41.2) 10 337 (73.6)
Central imaging registry 7 (10.3) 412 (2.9)
Central pathology/surgery
and central imaging registry
2 (2.9) 55 (0.4)
Ophthalmology department 14 (20.6) 1452 (10.3)
Rheumatology department 7 (10.3) 709 (5.1)
Multiple hospital departments 9 (13.2) 1006 (7.2)
Unclear 1 (1.5) 66 (0.5)
Specialty referring patients
Primary care 1 (1.5) 125 (0.9)
Hospital departments 3 (4.4) 481 (3.4)
Primary care and hospital departments 8 (11.8) 2701 (19.2)
Unclear 56 (82.4) 10 730 (76.4)
Laboratory results before treatment
No 8 (11.8) 2779 (19.8)
Yes 6 (8.8) 800 (5.7)
Unclear 27 (39.7) 5824 (41.5)
Not applicable 27 (39.7) 4634 (33.0)
Type of reference standard
TAB 38 (55.9) 11 207 (79.8)
Clinical diagnosisc 30 (44.1) 2830 (20.2)
Focus of diagnostic testing
Cranial arteries 53 (77.9) 12 543 (89.4)
Systemic arteries 1 (1.5) 63 (0.4)
Cranial and systemic arteries 14 (20.6) 1431 (10.2)
Abbreviations: GCA, giant cell arteritis; TAB, temporal artery biopsy.
a Percentages have been rounded andmay not total 100.
bA total of 4277 patients were classified as having GCA.
c Seven studies with the clinical diagnosis as the reference
standard46,68,71,75-77,82 also allowed evaluation of TAB as the reference
standard (558 patients). One study with the clinical diagnosis as the reference
standard68 also allowed evaluation of ultrasonography as the reference
standard (23 patients).
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diagnosis was typically based on clinical and laboratory find-
ings, imaging and/or TAB results, and a good initial response
to glucocorticoid treatment (eTable 5 in the Supplement). In
16 of the studies using clinical diagnosis as reference
standard,17,29,31,33,34,36,47,51,53,54,57,61,68,69,76,82 patients were
all followed up to verify that the clinical diagnosis was not
later revised. Only 1 study68 allowed us to evaluate imaging
as the reference standard in addition to the clinical diagnosis
and TAB.
Evaluation of Bias
Patient selection was the principal source of bias (eFigures 2
and 3 in the Supplement). Studies using TAB as the reference
standard may have been more prone to selection bias be-
cause a sufficient index of clinical suspicion is required to or-
der this invasive test. Conversely, studies using the clinical di-
agnosis as the reference standard were at high risk of bias
because the index test result contributed to the clinical diag-
nostic decision.
Diagnostic Value of Symptoms and Demographic Features
In studies reporting thesexofpatients (n = 7798),2605 (33.4%)
of patients were male and 5193 (66.6%) were female. Al-
though headache is considered to be a key symptom for GCA,
the positive and negative LRs for headache did not meet our
prespecified threshold for statistical significance (Table 2).
Double vision provided a positive LR of 1.72 (95% CI, 1.12-
2.63). PositiveLRsofmore than2.00were found for limbclau-
dication (6.01;95%CI, 1.38-26.16), jawclaudication (4.90;95%
CI, 3.74-6.41), and a previous diagnosis of polymyalgia rheu-
matica (2.07; 95%CI, 0.92-4.65),whereas being older than 70
years had a negative LR of less than 0.50 (0.48; 95% CI, 0.27-
0.86). The forest plots and HSROC curves indicated substan-
tial heterogeneity for all statistically significant index tests ex-
cept for jawclaudication (eFigures4and5 in theSupplement).
Overall, we found little evidence of publication bias by evalu-
ation of funnel plot asymmetry (eFigure 6 in the Supple-
ment). Symptoms reported by less than 4 studies are shown
in eTable 6 in the Supplement.
Diagnostic Value of Physical Signs and Laboratory Tests
A positive LR ofmore than 2.00 occurred for findings related
to temporal artery thickening (LR, 4.70; 95% CI, 2.65-8.33),
temporal artery loss of pulse (3.25; 95% CI, 2.49-4.23), tem-
poral tenderness (3.14; 95% CI, 1.14-8.65), an abnormal tem-
poral artery (2.29; 95% CI, 1.61-3.26), anterior ischemic optic
neuropathy (2.15; 95% CI, 1.53-3.03), erythrocyte sedimenta-
tion rate (ESR) of greater than 60 (2.40; 95%CI, 1.71-3.36), 80
(2.79; 95% CI, 1.78-4.37), and 100 mm/h (3.11; 95% CI, 1.43-
6.78), and a platelet count of greater than 400 × 103/μL all (to
convert to ×109/L, multiply by 1) (3.75; 95% CI, 2.12-6.64)
(Table 3). Negative LRs of less than 0.50 occurred for an ESR
of more than 40 mm/h (0.18; 95% CI, 0.08-0.44), more than
50mm/h (0.48; 95% CI, 0.38-0.62), andmore than 60mm/h
(0.42; 95%CI,0.28-0.61), CRP level of at least 2.5mg/dL (0.38;
95% CI, 0.25-0.59), or a CRP level of greater than the refer-
encevalue (0.40;95%CI,0.29-0.56).Overall,moderatehetero-
geneity and little funnel plot asymmetrywas observed (eFig-
ures4, 5, and6 in theSupplement). Physical findings reported
by fewer than 4 studies are shown in eTable 7 in the Supple-
ment.
Sensitivity Analyses
Results of our sensitivity analyses are provided in eTables 8
to 10 in theSupplement.We foundcomparableLRs inourcom-
parison of studies with different reference standards (TAB vs
clinical diagnosis) or study design (prospective vs retrospec-
tive). A pretreatment elevated CRP level showed a sensitivity
of90.1%(95%CI, 76.3%-96.3%)andanegativeLRof0.38 (95%
CI, 0.17-0.81) for a diagnosis of GCA. A pretreatment ESR of
greater than50mm/hhadasensitivityof87.5%(95%CI,78.3%-
93.1%) and negative LR of 0.27 (95% CI, 0.13-0.57).
Discussion
Main Findings
This updatedmeta-analysis provides more precise estimates
of LRs associated with symptoms, signs, and laboratory fea-
turesofGCA.Features that, if present, shouldupgrade the level
of suspicion for GCA are limb claudication; jaw claudication;
various temporal artery abnormalities; a platelet count of
greater than 400 × 103/μL; ESRs of greater than 60, 80, and
100mm/h; and anterior ischemic optic neuropathy. Features
that should downgrade the level of suspicion for GCA are 70
yearsoryounger; aCRP level in the reference rangeor less than
2.5mg/dL; and an ESR of no greater than 40, 50, or 60mm/h.
FormostpatientswithsuspectedGCA,nosingle feature is likely
to shift pretest probability sufficiently to render further in-
vestigation forGCAunnecessary.However, these likelihoodra-
tiosmay informclinicaldecisions, including selectionand tim-
ing of investigations, andwhether to immediately commence
high-dose glucocorticoid therapy or await further test
results.88,89
AssociationWith Other Studies
Our findings confirm and extend those of the previous
meta-analysis,11 which had included 21 studies of 2680 pa-
tients. Wewere able to show that an elevated ESR, especially
greater than 60mm/h, is informative in suggesting a diagno-
sis of GCA. We improved the precision and clinical utility
of the summary estimates. For example, the previous
meta-analysis11 estimated thepositive LR for double vision as
3.4 (95% CI, 1.3-8.6); with greater patient numbers, we esti-
mate the positive LR as 1.72 (95% CI, 1.12-2.63). We were also
able toevaluate thediagnostic accuracyof further features, in-
cluding transient lossof vision, cerebrovascular accident, limb
claudication, central retinal artery occlusion, CRP levels, and
platelet counts. Furthermore,weconducted sensitivity analy-
ses to evaluate for bias arising from choice of reference stan-
dard,prospectivevsretrospectivestudies,andwhetherall labo-
ratorytestswereexplicitlystatedasoccurringbefore treatment.
Various tools have been developed that could help to es-
timateGCAprobability.These tools requireassessmentofa lim-
ited set of clinical and laboratory features that were origi-
nally selected by expert opinion and thenweighted based on
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expert opinion or statistical methods.8,9 Interestingly, both
tools contain features, such as sex, thatwere not very helpful
in changing GCA probability according to our meta-analysis.
Some clinical features in these tools, such as symptom dura-
tion and alternative diagnosis,8 could not be included in our
meta-analysis owing to lack of published data.
Our meta-analysis indicates that some features consid-
ered classic for GCA, such as headache, scalp tenderness, and
Table 2. Diagnostic Accuracy of Demographics and Symptoms
Finding by study
No. of
patients (No.
of cohorts)
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Diagnostic OR
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
Demographics
Age, y
>60a 261 (7) 96.6 (76.0-99.6) 22.6 (15.4-31.8) 8.39 (1.05-67.11) 1.25 (1.12-1.39) 0.15 (0.02-1.13)
>70a 261 (7) 73.5 (49.5-88.7) 55.3 (39.2-70.3) 3.42 (1.68-6.96) 1.64 (1.29-2.09) 0.48 (0.27-0.86)x
>80b 208 (6) 19.0 (10.4-32.0) 85.1 (73.4-92.1) 1.33 (0.62-2.86) 1.27 (0.67-2.40) 0.95 (0,84-1.09)
Malec 7798 (42) 31.7 (29.6-33.9) 64.9 (62.5-67.2) 0.86 (0.77-0.96) 0.90 (0.84-0.97) 1.05 (1.01-1.09)
Symptoms
Cranial
Headached 6918 (36) 72.2 (68.3-75.8) 45.7 (39.1-52.4) 2.19 (1.72-2.78) 1.33 (1.19-1.48) 0.61 (0.53-0.70)
Temporal headachee 545 (4) 65.9 (37.4-86.2) 31.8 (14.1-57.1) 0.90 (0.56-1.46) 0.97 (0.82-1.14) 1.07 (0.78-1.47)
Scalp tendernessf 2951 (15) 38.9 (31.7-46.7) 78.9 (69.7-85.9) 2.39 (1.70-3.34) 1.85 (1.40-2.44) 0.77 (0.71-0.84)
Jaw claudicationg 6867 (35) 37.5 (33.8-41.3) 92.3 (89.6-94.4) 7.24 (5.45-9.62) 4.90 (3.74-6.41)x 0.68 (0.64-0.71)
Visual disturbanceh 3023 (25) 33.9 (29.6-38.4) 71.8 (66.7-76.4) 1.30 (1.06-1.60) 1.20 (1.04-1.39) 0.92 (0.86-0.98)
Loss of visioni 4585 (14) 21.7 (15.1-30.3) 85.3 (76.2-91.3) 1.61 (1.21-2.14) 1.48 (1.15-1.91) 0.92 (0.88-0.96)
Transient loss of visionj 1181 (9) 10.7 (7.1-16.0) 92.9 (86.6-96.4) 1.57 (0.88-2.82) 1.51 (0.88-2.60) 0.96 (0.92-1.01)
Double visionk 3799 (8) 6.5 (4.5-9.3) 96.2 (93.2-97.9) 1.76 (1.13-2.75) 1.72 (1.12-2.63) 0.97 (0.95-0.99)
Cerebrovascular accidentl 1089 (5) 2.6 (1.3-5.1) 95.9 (89.0-98.5) 0.62 (0.23-1.63) 0.63 (0.25-1.59) 1.02 (0.98-1.06)
Systemic
Constitutional
symptomsm
1274 (8) 62.5 (35.5-83.5) 46.8 (29.1-65.2) 1.47 (0.89-2.41) 1.17 (1.00-1.38) 0.80 (0.56-1.14)
Malaisen 1267 (10) 55.5 (44.0-66.4) 51.7 (38.8-64.4) 1.33 (1.02-1.75) 1.15 (1.00-1.33) 0.86 (0.75-0.99)
Anorexiao 1932 (8) 40.2 (28.0-53.8) 74.5 (64.5-82.5) 1.97 (1.51-2.57) 1.58 (1.33-1.88) 0.80 (0.71-0.91)
Weight lossp 2882 (18) 39.3 (31.0-48.3) 76.7 (72.2-80.6) 2.13 (1.64-2.77) 1.69 (1.44-1.98) 0.79 (0.71-0.89)
Feverq 3091 (23) 26.7 (19.8-34.9) 78.0 (68.4-85.3) 1.29 (1.03-1.62) 1.21 (1.01-1.46) 0.94 (0.90-0.99)
Other
Myalgiar 1855 (15) 39.8 (35.0-44.9) 57.5 (46.9-67.4) 0.90 (0.61-1.31) 0.94 (0.75-1.17) 1.05 (0.89-1.23)
PMRs 2814 (23) 33.4 (27.5-39.8) 74.3 (65.9-81.2) 1.45 (1.14-1.84) 1.30 (1.08-1.56) 0.90 (0.84-0.95)
Previous PMRt 519 (4) 19.1 (13.4-26.5) 90.8 (82.3-95.4) 2.32 (0.92-5.82) 2.07 (0.92-4.65) 0.89 (0.79-1.00)
Arthralgiau 656 (6) 25.4 (15.5-38.6) 73.3 (64.6-80.6) 0.94 (0.60-1.46) 0.95 (0.68-1.33) 1.02 (0.91-1.14)
Limb claudicationv,w 405 (6) 19.6 (12.5-29.4) 96.7 (84.2-99.4) 7.23 (1.62-32.21) 6.01 (1.38-26.16)x 0.83 (0.76-0.91)
Abbreviations: LR, likelihood ratio; OR, odds ratio; PMR, polymyalgia
rheumatica.
a From 7 of the analyzed studies.28,30,44,50,53,71,83
b From 6 of the analyzed studies.28,30,44,50,53,71
c From 43 of the analyzed studies.14,15,17,26,27,29-37,43-45,47,49-52,54,55,57,61,62,64,65,
69-71,73-77,80-82,84,87
d From 36 of the analyzed studies.15,17,29,32,35-37,39,43,45-49,52,54,55,57,58,61,64-66,69,
71-77,80,82-84,87
e From 4 of the analyzed studies.16,27,33,34
f From 15 of the analyzed studies.16,17,27,33,39,49,52,54,55,60,61,66,69,73,87
g From 35 of the analyzed studies.15,17,27,32-37,39,43,45-48,52-55,57,58,61,64,66,69,71-73,
75-77,80,82,84,87
h From 25 of the analyzed
studies.24,25,27,29,32,34,35,39,41,46,47,54,58,61,63-66,69,71,73,76,80,82,84
i From 14 of the analyzed studies.15,39,43,45,49,55,57,63,69,72,74,75,77,87
j From 9 of the analyzed studies.16,17,39,43,55,67,69,79,86
k From 8 of the analyzed studies.15,17,39,43,49,69,77,87
l From 5 of the analyzed studies.43,46,61,63,73
mFrom 8 of the analyzed studies.16,33,37,46,51,61,64,69
n From 10 of the analyzed studies.16,17,36,52,58,71,73,80,82,84
o From 8 of the analyzed studies.16,17,39,58,73,80,84,87
p From 18 of the analyzed studies.16,24,25,34,36,39,43,54,58,61,69,71,73,79,80,82,84,87
q From 23 of the analyzed
studies.16,32,35,36,39,41,43,47-49,52,54,55,57,58,61,65,69,71,73,75,80,84
r From 15 of the analyzed studies.16,35,36,43,47,52,55,57,58,61,69,73,75,80,84
s From 23 of the analyzed
studies.17,24,25,32-34,37,39,41,46,48,49,53,58,60,64-66,71,75,76,82,86
t From 4 of the analyzed studies.16,32,54,79
u From 6 of the analyzed studies.16,39,58,75,80,84
v From 6 of the analyzed studies.29,35,51,69,71,82
wLimb claudication was restricted to the arms in one study71 and to the legs in
another study.29
x Statistically significant due to summary estimate of the positive LR of greater
than 2.00 or the negative LR of less than 0.50 and a 95% CI not including
1.00.
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constitutional symptoms, have limited use for upgrading or
downgrading the clinical probability of GCA. This does not
mean,however, that these symptomsare irrelevant.Ourmeta-
analysis shows that the prevalence of these classic features is
high among patients with and without GCA, suggesting that
the diagnostic value of these symptomsmay have been used
up earlier in the care pathway.90 Headache is important in
prompting suspicion of GCA and onward referral to a special-
ist, but once that referral decision has been made, clinicians
should be cautious about overvaluing the diagnostic signifi-
cance of headache and should evaluate patients for the other
features identified inourmeta-analysis as informative for a fi-
nal diagnosis of GCA.
Limitations
Our study was limited by the quality of the studies included.
Although we performed a comprehensive search for pub-
lished studies,wecannot exclude that relevantdatawasomit-
ted owing to exclusion of non-English articles and confer-
enceabstracts.Nounpublisheddatawereobtainedvia contact
with authors.
Several sources of bias were present in our meta-
analysis. First, studies using TABmay have been at risk of se-
lection bias because the decision for TAB necessarily de-
pends on the presence of clinical and laboratory features to
justify this invasive test. Second, clinical diagnosis is subjec-
tive and reliesonclinical and laboratory features aswell as fur-
Table 3. Diagnostic Accuracy of Physical and Laboratory Findings
Finding by study
No. of
patients (No.
of cohorts)
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Diagnostic OR
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
Physical and fundoscopic
abnormalities
Any temporal artery
abnormalitya,b
3823 (13) 52.9 (39.3-66.0) 76.9 (64.6-85.9) 3.73 (2.30-6.06) 2.29 (1.61-3.26)c 0.61 (0.49-0.77)
Temporal tendernessd 658 (5) 51.4 (37.6-65.1) 83.6 (59.1-94.5) 5.41 (1.58-18.46) 3.14 (1.14-8.65)c 0.58 (0.43-0.79)
Temporal artery thickeninge 929 (8) 44.4 (31.3-58.2) 90.6 (81.8-95.4) 7.65 (4.04-14.48) 4.70 (2.65-8.33)c 0.61 (0.50-0.76)
Temporal artery
loss of pulsef
1227 (7) 38.2 (31.3-45.5) 88.2 (85.6-90.4) 4.63 (3.22-6.67) 3.25 (2.49-4.23)c 0.70 (0.62-0.79)
Temporal artery tendernessg 1136 (10) 36.0 (22.1-52.6) 81.4 (66.5-90.6) 2.46 (1.43-4.22) 1.93 (1.25-2.99) 0.79 (0.66-0.93)
AIONh 1181 (7) 23.9 (13.0-40.0) 88.9 (80.8-93.8) 2.51 (1.63-3.87) 2.15 (1.53-3.03)c 0.86 (0.75-0.97)
Ischemic optic neuropathyi 682 (4) 21.9 (10.9-39.3) 87.3 (75.5-93.9) 1.94 (0.83-4.51) 1.73 (0.86-3.49) 0.89 (0.76-1.05)
CRAOj 647 (5) 6.5 (3.1-12.9) 95.6 (85.6-98.7) 1.53 (0.48-4.89) 1.49 (0.49-4.53) 0.98 (0.93-1.03)
Laboratory findings
Anemiak 2725 (14) 54.5 (41.2-67.2) 55.3 (42.4-67.6) 1.48 (1.22-1.79) 1.22 (1.10-1.36) 0.82 (0.74-0.92)
CRP level elevatedl,m 1849 (9) 87.4 (80.4-92.1) 31.4 (25.4-38.0) 3.16 (2.21-4.53) 1.27 (1.20-1.35) 0.40 (0.29-0.56)c
CRP level ≥2.5 mg/dLn 1121 (5) 79.2 (63.5-89.3) 54.2 (40.1-67.7) 4.50 (2.84-7.14) 1.73 (1.41-2.12) 0.38 (0.25-0.59)c
ESR elevatedo,p 3429 (15) 82.6 (74.4-88.6) 33.8 (25.6-43.1) 2.43 (1.62-3.65) 1.25 (1.12-1.39) 0.51 (0.37-0.71)
ESR>40 mm/hq 546 (9) 93.2 (79.7-97.9) 37.5 (21.1-57.4) 8.17 (3.40-19.62) 1.49 (1.16-1.92) 0.18 (0.08-0.44)c
ESR>50 mm/hr,s 1966 (18) 78.9 (71.7-84.7) 43.5 (34.1-53.4) 2.88 (2.05-4.05) 1.40 (1.22-1.60) 0.48 (0.38-0.62)c
ESR>60 mm/ht 270 (6) 70.7 (56.2-81.9) 70.5 (57.5-80.9) 5.77 (3.26-10.23) 2.40 (1.71-3.36)c 0.42 (0.28-0.61)c
ESR>80 mm/ht 270 (6) 50.7 (31.2-69.9) 81.8 (74.4-87.4) 4.62 (2.07-10.29) 2.79 (1.78-4.37)c 0.60 (0.41-0.90)
ESR>100 mm/hu 368 (7) 24.2 (13.0-40.6) 92.2 (81.1-97.1) 3.79 (1.60-8.97) 3.11 (1.43-6.78)c 0.82 (0.70-0.96)
Platelet count
>400 × 103/μLv,w
2316 (5) 45.8 (33.0-59.3) 87.8 (81.1-92.3) 6.08 (2.74-13.49) 3.75 (2.12-6.64)c 0.62 (0.47-0.80)
Abbreviations: AION, anterior ischemic optic neuropathy; CRAO, central retinal
artery occlusion; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
LR, likelihood ratio; OR, odds ratio.
SI conversion factors: To convert CRP tomg/L, multiply by 10; platelet count to
×109/L, multiply by 1.
a A precise definition was typically lacking; it was for instance reported as
abnormal temporal artery or temporal artery abnormality.
b From 13 of the analyzed studies.15,33,41,42,46,49,52,54,55,64,71,80,84
c Statistically significant due to summary estimate of the positive LR of greater
than 2.00 or the negative LR of less than 0.50 and a 95% CI not including
1.00.
d From 5 of the analyzed studies.34,36,43,65,77
e From 8 of the analyzed studies.24,25,34,35,63,71,73,82
f From 7 of the analyzed studies.16,43,47,63,71-73
g From 10 of the analyzed studies.16,47,53,57,58,63,71,73,75,83
h From 7 of the analyzed studies.43,48,56,60,63,67,86
i From 4 of the analyzed studies.37,63,75,79
j From 5 of the analyzed studies.43,56,67,79,86
k From 14 of the analyzed studies.30,32,35,39,46,50,52,64,71,73,80,82,84,87
l Defined as at least 0.5 mg/dL unless other laboratory-specific reference values
were reported.
mFrom 9 of the analyzed studies.14,28,37,59,61,63,64,66,68
n From 5 of the analyzed studies.28,54,68,70,85
oDefined as greater than 20mm/h in men and greater than 30mm/h in
women, unless other laboratory-specific reference values were reported. In 8
of 32 (25%) studies reporting the ESR, it was clearly stated theWestergren
method was used.
p From 15 of the analyzed studies.14,16,26,28,30,37,40,44,47,48,57,59,66,78,87
q From 9 of the analyzed studies.28,30,38,44,53,65,77,80,84
r Includes studies reporting an ESR of at least 50mm/h.
s From 18 of the analyzed studies.26,28,30-32,37,38,44,54,62,64,65,70,71,73,81-83
t From 6 of the analyzed studies.28,30,38,44,53,65
u From 7 of the analyzed studies.28,30,32,38,44,53,65
v Includes studies reporting a platelet count of at least 400 × 103/μL.
wFrom 5 of the analyzed studies.26,37,40,70,85
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ther tests; this circularity could lead to overestimation of the
diagnostic accuracy of index tests. Third, many studies were
retrospective cohort studies,whichcouldhave introduced fur-
ther selection bias. We mitigated these risks of bias by per-
forming sensitivity analyses, which did not show substantial
differences between studies with distinct reference stan-
dards or between studies with retrospectively and prospec-
tively gathered data.
The reference standards forGCAmayhaveadditional limi-
tations. Although the sensitivity of TABmay be 77% for fulfil-
ment of the American College of Rheumatology 1990 criteria
forGCA,91 it is likely lower for theclinicaldiagnosis indailyclini-
calpractice.6Somestudies inourmeta-analysis46,68,71,75-77,82 re-
portedasubgroupofpatientswithTABfindings thatwerenega-
tive for GCA. Patients with GCA may have had TAB findings
negative forGCA in other studies, but these patientswere sim-
ply classified as not having GCA. Thus, the diagnostic accu-
racyof clinical and laboratory featuresmighthavebeenunder-
estimated.TheclinicaldiagnosisofGCAmightbesubjectiveand
strongly related to the experience of the individual physician
making the diagnosis. The clinical diagnosis was only ascer-
tained by follow-up in aminority of studies. Nevertheless, we
observed comparable LRsof clinical and laboratory features in
studies using TAB or the clinical diagnosis as the reference
standard.
A clear definition of symptomswas lacking in the studies
included in our meta-analysis. This might be relevant for a
symptom such as jaw claudication. Jaw claudication typi-
cally occurs after 2 to 3 minutes of chewing,92 but temporo-
mandibular joint pain is common in older people and also
causespainwithchewing.Lackofacleardefinitionof jawclau-
dication might possibly inflate the LR of this clinical feature,
because it allows clinicians to classify aching on chewing as
either jawclaudicationor temporomandibular jointpainbased
on the clinical judgment thatGCA is likely or not. Because jaw
claudication is not described in any other disease and might
be considered almost pathognomonic of GCA, cliniciansmay
bereluctant todocument jawclaudicationunless theyare fairly
sure for other reasons that the patient has GCA.
Glucocorticoid treatment may be commenced immedi-
ately when GCA is suspected. This treatment could have af-
fected index test results, particularly the laboratory tests. It
was surprising that only few reports explicitly stated that the
laboratory test resultswereobtainedbefore treatment.Oursen-
sitivity analysis for pretreatment laboratory measures could
only be performed for an elevated CRP level and an ESR of
greater than 50 mm/h. These pretreatment laboratory fea-
tures tended to showbetter sensitivity and negative LRs than
those obtained in the main study analysis.
The meta-analysis method we used required us to
dichotomize continuous variables associated with GCA (age
and laboratory values), which is inefficient and likely results
in underestimation of diagnostic utility. However, indi-
vidual patient data meta-analysis would have been needed
to overcome this.
Studyheterogeneitywasobserved for various clinical and
laboratory featureswith relevant LRs. Additional prospective
studies areneeded to confirm the summaryestimatesof these
features.We therefore recommend that complete sets of clini-
cal and pretreatment laboratory data are reported in diagnos-
tic cohort studies, either in summary tablesor as rawdata.This
process would allow investigators to determine summary es-
timates of diagnostic accuracy parameters with more preci-
sion. Prospective studies would ideally consist of all patients
who have been evaluated for GCA by every specialty or de-
partment in a hospital.90
Conclusions
This systematic review andmeta-analysis highlight the clini-
cal and laboratory features that may be informative in mak-
ingadiagnosisofGCAandthat shouldbeassessedwhenevalu-
ating patients with suspected GCA. They should also be
reported in futurediagnostic cohort studies. Clinicians should
obtain a comprehensive history, physical examination, and
laboratoryevaluationforeachpatientsuspectedofhavingGCA.
No single symptom, physical sign, or laboratory test is suffi-
cient to completely rule in or rule out GCA. An additional
imaging test or TAB is typically needed to make a confident
diagnosis of GCA. Our study could not determinewhether in-
dividual LRs can be combined, or whether there is collinear-
ity between particular features (eg, ESRs and CRP levels with
constitutional symptoms). Nonetheless, this study provides
important data that could inform a future bayesian probabil-
ity revision approach to investigation, diagnosis, and man-
agement of suspected GCA,whichwould need to be prospec-
tively validated in future studies.
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